Radiopharmaceuticals in prostate cancer - radium-223 episode 1

Episode 1 May 12, 2021 00:30:53
Radiopharmaceuticals in prostate cancer - radium-223 episode 1
COR2ED Medical Education
Radiopharmaceuticals in prostate cancer - radium-223 episode 1

May 12 2021 | 00:30:53

/

Show Notes

Dr. Tanya Dorff (City of Hope Comprehensive Cancer Center, Los Angeles, USA) and Dr. Phillip Koo (Banner MD Anderson Cancer Center, Arizona, USA) discuss the latest developments in the field of radiopharmaceuticals and their use in Prostate Cancer. They are also joined by guest speaker Dr. Neal Shore (Carolina Urologic Research Center, North Carolina, USA).

In this first episode, the experts focus on the alpha emitter, Radium-223 which received regulatory approval on the basis of the phase 3 ALSYMPCA trial in patients with metastatic castration resistant prostate cancer (mCRPC) and symptomatic bone metastases. They consider mechanism of action and discuss key results from the trial and the safety profile.

The experts also review the ERA-223 and PEACE-III randomised trials which investigated the use of Radium-223 in combination with next generation androgen receptor inhibitors (ARIs). A number of real-world evidence studies are also reviewed as the experts consider where radium-223 fits into the overall treatment sequence for mCRPC patients. Radiation safety and general considerations for delivering therapy with radiopharmaceuticals are also discussed.

Other Episodes

Episode

November 27, 2023 00:19:16
Episode Cover

Perioperative Thromboprophylaxis Revisited

Thrombotic risk is a constant threat in perioperative patients, but it has decreased with the evolution of surgical technology.  Do you know how to...

Listen

Episode 18

July 26, 2023 00:24:55
Episode Cover

An introduction to molecular testing: what and when across the patient journey

COR2ED Medical Education: This podcast episode provides an introduction to molecular testing in the diagnosis and treatment of cancer.  Prof. David Hong from MD...

Listen

Episode 3

March 16, 2022 00:19:56
Episode Cover

High-Risk Cytogenetics in MM: Choosing the Best Treatment Regimen Ep 3

COR2ED Medical Education: In this podcast episode, myeloma experts Dr. María Victoria Mateos (Haematologist at the University Hospital Salamanca, Spain) and Dr. Alexander Lesokhin...

Listen